Quick Answer
GALECTIN THERAPEUTICS INC reported Research And Development Expense of $14.29 million for the year ending 2025.
- GALECTIN THERAPEUTICS INC showed a decrease of -60.9% in Research And Development Expense from 2024 to 2025.
- This data is from GALECTIN THERAPEUTICS INC's annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2010: $234.0 thousand | Q3 2010: $313.0 thousand | Q1 2011: $744.0 thousand | Q2 2011: $1.29 million | Q3 2011: $655.0 thousand | Q1 2012: $901.0 thousand | Q2 2012: $1.22 million | Q3 2012: $1.41 million | Q1 2013: $1.75 million | Q2 2013: $1.35 million | Q3 2013: $1.19 million | Q1 2014: $2.77 million | Q2 2014: $1.59 million | Q3 2014: $1.98 million | Q1 2015: $3.14 million | Q2 2015: $2.60 million | Q3 2015: $4.46 million | Q1 2016: $4.38 million | Q2 2016: $4.23 million | Q3 2016: $3.29 million | Q1 2017: $3.77 million | Q2 2017: $3.44 million | Q3 2017: $3.50 million | Q1 2018: $2.30 million | Q2 2018: $1.48 million | Q3 2018: $1.51 million | Q1 2019: $646.0 thousand | Q2 2019: $1.52 million | Q3 2019: $1.50 million | Q1 2020: $2.14 million | Q2 2020: $4.68 million | Q3 2020: $4.78 million | Q1 2021: $4.90 million | Q2 2021: $6.45 million | Q3 2021: $6.61 million | Q1 2022: $8.06 million | Q2 2022: $8.07 million | Q3 2022: $6.60 million | Q1 2023: $8.80 million | Q2 2023: $7.37 million | Q3 2023: $7.73 million | Q1 2024: $8.05 million | Q2 2024: $9.81 million | Q3 2024: $7.60 million | Q1 2025: $6.49 million | Q2 2025: $3.26 million | Q3 2025: $2.61 million.
- Over the full 16 years of available data (2010 to 2025), GALECTIN THERAPEUTICS INC's Research And Development Expense has grown by 1,240.5%.
- Historical annual values: Fiscal year 2025: $14.29 million | Fiscal year 2024: $36.57 million | Fiscal year 2023: $32.13 million | Fiscal year 2022: $31.74 million | Fiscal year 2021: $23.82 million | Fiscal year 2020: $17.98 million | Fiscal year 2019: $7.47 million | Fiscal year 2018: $6.47 million | Fiscal year 2017: $11.72 million | Fiscal year 2016: $15.33 million | Fiscal year 2015: $13.11 million | Fiscal year 2014: $8.43 million | Fiscal year 2013: $5.69 million | Fiscal year 2012: $4.53 million | Fiscal year 2011: $3.55 million | Fiscal year 2010: $1.07 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: